HPCAL1 and Alzheimer disease: In addition, no differences in VILIP3 expression were observed in the hippocampus of 3-month-old mice in the present study, whereas in in vitro experiments VILIP3 showed a dose-dependent decrease in response to Aβ1−42, suggesting that VILIP3 is not yet affected in the early stages of AD but may be involved in disease progression.